{"id":"NCT02797951","sponsor":"Eli Lilly and Company","briefTitle":"A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache","officialTitle":"A Phase 3b Multicenter, Single-Arm, Open-Label Safety Study of LY2951742 (Galcanezumab) in Patients With Episodic or Chronic Cluster Headache","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-07-13","primaryCompletion":"2021-01-21","completion":"2021-01-21","firstPosted":"2016-06-14","resultsPosted":"2022-02-10","lastUpdate":"2022-02-10"},"enrollment":165,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Episodic Cluster Headache","Chronic Cluster Headache"],"interventions":[{"type":"DRUG","name":"Galcanezumab","otherNames":["LY2951742"]}],"arms":[{"label":"Galcanezumab","type":"EXPERIMENTAL"}],"summary":"The main purpose of this study is to assess the long-term safety and tolerability of galcanezumab administered up to once monthly in participants with episodic or chronic cluster headache who have completed study I5Q-MC-CGAL (NCT02397473) or study I5Q-MC-CGAM (NCT02438826).","primaryOutcome":{"measure":"Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious AEs (SAEs)","timeFrame":"Baseline through End of Study (Up to 4 Years)","effectByArm":[{"arm":"Galcanezumab 300 mg SC","deltaMin":119,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":7},"locations":{"siteCount":40,"countries":["United States","Belgium","Canada","Denmark","Finland","France","Germany","Greece","Italy","Netherlands","Spain","United Kingdom"]},"refs":{"pmids":["35633025"],"seeAlso":["https://trials.lillytrialguide.com/en-US/trial/WEzAu0Rzqgg2YY8AKeKSC"]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":164},"commonTop":["Nasopharyngitis","Influenza","Arthralgia","Back pain","Bronchitis"]}}